A Review of the Actions of D-cycloserine, a Putative Nootropic Agent, at the NMDA Receptor Complex-Associated Glycine Binding Site

J.W. Allen*, B.S.

* To whom correspondence should be addressed: NW, Georgetown University Medical Center, 3900 Reservoir Road, Washington, D.C. 20007 USA

INTRODUCTION

Compounds that enhance the acquisition and retrieval of information, known broadly as nootropics, have long been sought. The development of nootropics has obvious clinical importance for the treatment of cognitive dysfunction associated with aging and pathological conditions such as Alzheimer's disease. Following the discovery of the N-methyl-D-aspartate (NMDA) glutamate receptor and its possible role in learning and memory, compounds acting at this receptor complex have been investigated for cognition-enhancing activity. One such compound is D-cycloserine (DCS), a broad-spectrum antibiotic currently administered at doses of 0.5 to 1.0 grams per day for the treatment of Mycobacterium tuberculosis infections (1,2), which has been found to interact with the NMDA receptor complex (3).

This review will focus on the actions of DCS as mediated by the NMDA receptor complex, with emphasis placed upon the compound's possible nootropic activity. Following a brief discussion of the NMDA receptor, the interactions of DCS with this receptor will be presented, and studies investigating the use of DCS as a possible treatment for cognitive disorders will be reviewed.

THE NMDA RECEPTOR COMPLEX

The NMDA receptor complex is a voltage-dependent, ligand-gated ion channel with a high degree of calcium permeability, which has been postulated to exist as an heteromeric pentamer with a central ion-conducting pore (4-6). Even before this complex was discovered, its importance in learning and memory had been illustrated through a decrease in the severity of mental retardation in patients to whom glutamic acid was administered (7), and through a demonstrable increase in maze learning in rats with the use of NMDA agonists (8). After the discovery of long-term potentiation (LTP) (9)--a long-lasting increase in synaptic efficacy inducible in some areas of the CNS following tetanic stimulation, and a possible molecular mechanism in the biochemical cascade that leads to the formation of memories--it was demonstrated that the NMDA receptor complex was required for the induction of LTP in certain brain regions (10-13). Using a variety of techniques, including blockade with NMDA antagonists, investigators discovered that the activation of the NMDA receptor complex appeared to be involved in certain forms of learning and memory (14-17).
Glutamate is an endogenous ligand for the NMDA receptor complex (18); however, it is now clear that glycine also interacts with this receptor. The co-administration of 3 μM glycine and 300 μM NMDA to Xenopus oocytes expressing the NMDA receptor elicits an increase in the maximum inward current over that seen with NMDA alone (19). Furthermore, the co-administration of these two compounds at similar concentrations to Xenopus oocytes expressing the NMDA receptor or to hippocampal neurons in vitro decreases the amount of apparent NMDA receptor desensitization that occurs with glutamate alone (19-21). In addition, NMDA has been found to increase the release of norepinephrine from rat hippocampal synaptosomes, which represent dissociated nerve terminals, and this release is enhanced by glycine and DCS, a glycine partial agonist (22). Using [3H]strychnine, a radiolabeled glycine antagonist, and [3H]glycine, it was demonstrated that two separate glycine-binding sites exist within the CNS: strychnine-sensitive (SS) sites, which have the highest density in the medulla, pons, and spinal cord; and strychnine-insensitive (SI) sites, which are found mainly within the cerebral cortex and cerebellum (23). The SS sites represent the glycine-coupled chloride ion channel, while the SI sites correlate with the glycine binding site associated with the NMDA receptor complex. This finding, coupled with the discovery of the NMDA receptor-associated glycine binding site (24), suggested that glycine may influence the activity of glutamate at the NMDA receptor complex.

Most investigators now agree that glycine is an absolute requirement for the activation of the NMDA receptor-associated cation channel, and it has been proposed that glycine and glutamate should be termed co-agonists (5,19,25-27). However, some investigators have suggested that glycine may be required to activate the NMDA receptor complex only under conditions of low glutamate concentrations (28,29), although most of the current research does not appear to support this theory. Kinetic modeling and binding studies have indicated that the NMDA receptor complex contains two binding sites for glutamate and two for glycine (30-33), and the glutamate and glycine binding sites are postulated to exist on the same protein (34). The exact nature of the interaction between these two ligands is unknown, as the reports of allosteric coupling are controversial and contradictory. Kinetic modeling of these interactions has suggested that the two ligands may show negative allosteric coupling (5,30), whereas binding studies have indicated that glutamate increases the level of [3H]glycine binding (35-37) and glycine similarly increases the level of [3H]glutamate binding (38,39). The latter studies suggest that glutamate and glycine exhibit positive allosteric coupling. Nonetheless, it is apparent that both glutamate and glycine binding is required for the activation of the NMDA receptor-associated cation channel.

Although the activation of the NMDA receptor complex requires the binding of both co-agonists, only glutamate, which exhibits the characteristics of transient release, has been described as a 'true' neurotransmitter, while glycine appears to be present continuously in the synaptic space (5). There is currently much debate concerning whether the levels of glycine in the CNS extracellular fluid (ECF) are sufficient to saturate the NMDA receptor-associated glycine binding sites. Because glycine is one of the most abundant amino acids in nature (it has been found in significant concentrations even in distilled water) (19), measurements of glycine in the ECF have been controversial (40). Direct measurements have found micromolar concentrations of glycine in the ECF, which is sufficient to saturate the SI glycine binding sites (41). In vivo studies utilizing rats have reported that the co-administration of NMDA and glycine agonists directly into the ventrobasal thalamus has only infrequently yielded small increases in NMDA receptor activation over that produced by NMDA alone (41). In vitro studies with brain slices have generally found no increase in the activation of the NMDA receptor complex (25,42), or only small increases (43), when an NMDA agonist is co-administered with glycine. These studies have led some investigators to hypothesize that the endogenous ECF glycine concentration may be enough to saturate the NMDA receptor complex in vivo (12).

However, saturation of the NMDA receptor-associated glycine binding sites, if it is a true phenomenon, may not occur in every brain microenvironment (44), such as that of the mossy fiber input to the cerebellar granule
The glycine concentration in the neonatal rat hippocampus has been suggested to be at sub-saturating levels, as the administration of glycine facilitates the response of NMDA in the hippocampus of the neonatal rat, but not of the adult (44). Furthermore, the increase in cerebellar cyclic GMP, which occurs with the administration of NMDA agonists in vivo, has been shown to occur with the administration of glycine agonists (46-48), and glycine agonists have increased the seizure-inducing potency of NMDA agonists when they are co-administered (49). These data, along with the discovery of specific glycine transporters in the CNS (50), indicate that the levels of glycine in the ECF may not always exist at saturating concentrations, especially at the synaptic cleft (51). It has been suggested that in areas of high NMDA receptor density, such as the hippocampus, glycine may be differentially regulated by transporters so that glycine remains at sub-saturating concentrations (50,52).

Whether due to regional differences in ECF concentrations of glycine, or to regional differences in the subunits used to assemble the heteromeric NMDA receptor complex, both in vivo and in vitro studies suggest that glycine has site-specific characteristics within the CNS (53,54). The increase in \([^3]H\)glutamate binding that occurs with glycine administration is dependent upon the area of the CNS under investigation, suggesting that regional heterogeneity exists for the glycine domain of the NMDA receptor complex (39,55). The various pharmacological actions of NMDA antagonists also appear to be differentially modulated by glycine (56), which may be attributable to regional differences in glycine concentrations or to regional differences in the NMDA receptor complex.

In addition, the NMDA receptor complexes may not all be sensitive to glycine binding: for example, the co-administration of glycine with NMDA in the striatum elicits only a small increase in NMDA binding when compared with the administration of NMDA alone (29). Therefore, it is difficult to predict the actions of glycine agonists or antagonists upon a particular function, such as learning or memory, based solely on the expected activation or repression of the NMDA receptor complex.

Nonetheless, it is apparent that the regulation of the NMDA receptor complex by glycine is consistent in some regards, as glycine antagonists resemble NMDA antagonists in most respects (25). Like NMDA antagonists, glycine antagonists have been found to exhibit anticonvulsant (57-59), neuroprotective (60), and anxiolytic (61,62) activities. Significant side effects of NMDA antagonists have been reported, including the induction of heat-shock proteins, some of which are markers of neuronal damage (63,64). In contrast, glycine antagonists apparently have no significant toxicity, even at high doses (25). Similarly, whereas glycine agonists may only increase NMDA receptor function to the physiologic maximum, the NMDA agonists exhibit considerable toxicity (65-67), potentially inducing excessive stimulation and, ultimately, cell death (68). Glycine agonists and antagonists appear to have a greater safety margin than NMDA agonists and antagonists (25,68,69), and therefore may prove to be more useful clinically (65,70).

**D-cycloserine**

D-cycloserine (DCS) has been found to interact with the SI glycine binding site associated with the NMDA receptor complex (3,71), and pharmacokinetic studies have indicated that DCS exhibits approximately 15-fold less affinity for this glycine binding site than glycine (72,73). The intrinsic activity of DCS was estimated at 40% to 50% (3,74), although some reports have placed this value as high as 70% (66) or 86% (73). Regardless, DCS can be considered to act as a partial agonist at the NMDA receptor-associated glycine binding site (3,28,47,66,73-75). The in vivo agonist actions of DCS at the NMDA receptor complex can be attributed to agonism of the glycine binding site, and not to an increase in glutamate release, as doses as high as 320 mg/kg in rats and mice failed to induce any changes excitatory amino acid levels in the CNS (76).

DCS has been reported to have good oral bioavailability (2,66), but the degree to which it crosses the blood-brain barrier exhibits inter-species variability. It has been reported that only 17% to 20% of DCS crosses the blood-brain barrier in mice (56) and rats (76), while studies in humans have indicated that DCS freely crosses
this barrier (2,77). The half-life of DCS in the mouse is approximately 23 minutes (78), indicating that the drug is rapidly cleared. DCS has a favorable toxicity profile (66,77), and most studies report that even at high doses of up to 320 mg/kg, the compound has no appreciable side effects in mice and rats (56,79-81). However, various adverse reactions to DCS involving the CNS have been noted in humans. For example, DCS has been reported to induce tremor, dysarthria, psychotic states, paranoid reactions, catatonic reactions, clinical depression, hyperreflexia, and paresis (2). In addition, the drug is generally contraindicated in individuals with a history of epilepsy (2), as convulsions have been reported in some patients (82).

Studies with DCS have illustrated the myriad effects that can be pharmacologically manipulated by drugs acting at the NMDA receptor complex. DCS has been reported to decrease the pain response elicited by prolonged chemical noxious stimuli in mice (80), to enhance the development of rapid tolerance to ethanol in rats (83), and to act as a sociotropic (approach-promoting) agent in mice (84). Although DCS is a glycine partial agonist and, therefore, would be expected to exhibit either agonist or antagonist characteristics, depending upon the glycine concentration, it does not provide the same protection that NMDA antagonists exhibit against glutamate-induced neurotoxicity in cultured cerebellar granule neurons (85).

However, in a similar manner to the NMDA antagonists, DCS has been reported to have anxiolytic properties in rat and mouse anxiety models. Intraperitoneal injections of DCS at doses of 30 - 300 mg/kg block the fear-potentiated acoustic startle effect in rats, a model that is used to assess the anxiolytic activity of compounds (86). No anxiolytic effect was noted when the concentration of DCS was 10 mg/kg, the lowest dose utilized in this study. Similarly, in a mouse punishment procedure, wherein mice are trained to avoid a darkened chamber with the use of a mild electric shock, DCS exhibited anxiolytic properties only at the dose of 1 mg/kg, and not at five times this dose (87). Although DCS acts as an anxiolytic in both models, the dose-response curve generated is dependent upon the paradigm utilized and the neural pathways under investigation. This phenomenon is apparent in all of the pharmacological effects of DCS.

DCS acts as an anticonvulsant in certain animal models; however, this property only emerges at doses greater than 100 mg/kg, which are generally higher than those required to exhibit its other properties (76,88). DCS has been reported to have anticonvulsant activities against maximal electroshock seizures in rats (56,71,81,89). In addition, DCS elicits almost complete suppression of kainate-induced seizures in rats (79), and antagonizes tonic convulsions induced by pentylenetetrazol (89). Some investigators have reported that DCS raises the seizure threshold in fully amygdala-kindled rats, wherein the amygdala was repeatedly stimulated so that an increased susceptibility to seizures was produced (90,91). In contrast, others have suggested that DCS is ineffective in this model (89). DCS appears to have no antagonistic effects on convulsions induced by (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (92), clonic convulsions induced by pentylenetetrazol, electrically-induced nonkindled hippocampal seizures, or strychnine-induced tonic convulsions (89). Therefore, the anticonvulsant activity of DCS, in a similar manner to its anxiolytic properties, may be model and neural pathway dependent.

The administration of high doses of DCS, up to 320 mg/kg, in naive mice does not have a proconvulsant effect (56), and DCS does not induce the paroxysmal activity in the limbic brain regions of kindled rats that has been seen with the administration of glycine antagonists and NMDA antagonists (93). In contrast, high doses of DCS in fully amygdala-kindled rats has been shown to be proconvulsant (91). Furthermore, DCS has been reported to act as a proconvulsant agent in humans, as it has induced tonic-clonic and absence seizures in susceptible individuals (2). These data indicate that DCS may act as an agonist in some animal models and as an antagonist in others. These findings may be related to the differential regulation of ECF glycine concentrations in the different micro-environments involved in each of these models; if the ECF glycine concentration at a particular synapse is enough to saturate the NMDA receptor-associated binding sites, then DCS could act as a glycine antagonist because of its lower intrinsic activity. However, if the ECF synaptic glycine concentration is at sub-saturating levels, then DCS may act as a glycine agonist.
The cognitive-enhancing properties of NMDA agonists have been known for some time (7,8) and, because of their interaction with the NMDA receptor complex, it has been speculated that glycine agonists would have similar properties. At the doses used in most of the studies of nootropic activity, DCS has no apparent effect upon the motivational state or the motor skills of experimental animals (94), suggesting that the actions of DCS in these studies are most likely due to specific effects on learning and memory. Although most of the research on the nootropic effects of DCS have utilized spatial memory tasks, DCS has been tested in other paradigms; for example, DCS was found to increase the response acquisition rate for rabbits in an eye-blink conditioning model (95).

In addition, the nootropic effects of DCS were examined in a punishment procedure involving a passive avoidance test. In this model, rats or mice are trained to avoid a chamber in which the animal had previously received an electric shock. To assess learning- or memory-enhancing properties of compounds, drugs are administered before or after the training, respectively, and the latency to enter the chamber on a subsequent trial is recorded. A study utilizing mice trained with a mild electric shock to avoid a darkened chamber found that DCS had no effect on learning when administered at a dose of 1 mg/kg or 5 mg/kg prior to training (87). However, the NMDA antagonists AP7 and MK-801 exhibited memory-impairing activity in this model that was not seen with either dose of DCS (87), and may be a result of its intrinsic activity at the NMDA receptor complex. A separate study, in which rats were trained to avoid one of two chambers with the use of a mild electric shock, found DCS to be effective in increasing the latency time to enter a chamber at doses of 0.3 - 10 mg/kg (72). The difference between these two studies may be attributable to species differences in sensitivity to DCS, although this explanation is unlikely, as other paradigms that utilize mice have found increases in learning or memory with similar doses to those used in rats. Therefore, it is more likely that the paradigm that made use of the darkened chamber may not be sensitive enough to detect the subtle changes in cognition that may result from DCS administration.

Most investigators have found that DCS administration in rats and mice promoted spatial learning. Retention of a thirst-motivated linear maze task was enhanced by the administration of 10 mg/kg, 20 mg/kg, or 80 mg/kg of DCS to mice immediately following training (66). In addition, a dose of 3 mg/kg of DCS administered 20 minutes prior to training facilitated acquisition in this task. These data suggest that DCS may have effects on both spatial memory storage and retention. Weakly-trained mice injected with 20 mg/kg of DCS also exhibited greater retention of an electric shock-motivated T-maze task (96). However, this increase was not seen with doses of DCS less than 5 mg/kg or doses greater than 40 mg/kg, indicating that although the two models—the thirst-motivated linear maze and the electric shock-motivated T-maze tasks—both test spatial learning and memory, each task is characterized by a distinct dose-response curve. Furthermore, a study utilizing rats in a food-motivated T-maze task found no increase in spatial learning with a DCS dose of 3 mg/kg, but did find that this dose of DCS increased the acquisition of a reversal task in which rats were trained to enter one arm of the T-maze and subsequently trained to enter the other (72).

Because most of the available paradigms that measure changes in learning and memory may lack the sensitivity necessary to detect small increases or decreases in cognitive function in healthy animals, many investigators have utilized lesioned animals or pharmacologically-induced deficits in learning and memory to amplify the observable effects of nootropic compounds. Rats subjected to bilateral quinolinic acid-induced hippocampal lesions, which induce cell loss but do not completely destroy the hippocampus, exhibit working memory deficits that are reversible with the administration of 12 mg/kg of DCS prior to testing in a radial arm maze (97). Deficits in spatial memory, such as impairments in the water-maze or the T-maze paradigms, may also be induced by injections of scopolamine in healthy rats, which blocks the cholinergic input to the hippocampus that is required for its functioning in memory tasks (98). These deficits are reversible by the administration of doses of DCS ranging from 0.3 - 30 mg/kg (99,100).
Scopolamine-induced learning and memory deficits have also been investigated in primates. Injections of 3-14 mg/kg of DCS given to rhesus monkeys failed to reverse a scopolamine-induced deficit of a spatial delayed response task; however, the highest dose of DCS administered, 14 mg/kg, elicited slight improvements in particular tests (101). In contrast, elderly and young healthy human volunteers who received both scopolamine and DCS exhibited marked improvement in tasks of logic and verbal functions over that of volunteers who received scopolamine alone (102,103). This data again illustrates that the dose-response curve and sensitivity of a particular task to DCS is dependent upon the function analyzed. For example, although most studies utilizing more than one dose of DCS found an inverted u-shaped dose-response curve for nootropic activity, each task and each species investigated exhibited a different optimal dose of DCS; this value ranged from a dose of 1 mg/kg for the reversal of scopolamine-induced deficits in rats (100) to 20 mg/kg for the retention of a passive avoidance task in mice (96).

**THE USE OF D-CYCLOSERINE IN AGING AND COGNITIVE DISORDERS**

In the past, clinicians have attempted to use NMDA agonists to enhance cognitive function in conditions such as mental retardation (7), and recently focus has been placed upon the possible therapeutic benefit of glycine agonists. As noted above, the glycine agonists may exhibit a greater safety margin and, therefore, these compounds may be more beneficial for therapeutic administration than the NMDA agonists because of the possible toxicity of the latter (25,65,68,70). Because aging is associated with decrements in learning and memory functions, some investigators have attempted to reverse these changes with glycine agonists. Aged rats exhibit decreases in the NMDA-induced release of norepinephrine from rat hippocampal synaptosomes, and DCS has been reported to increase this release, indicating a possible rationale for the use of DCS in the reversal of age-related changes (22). Furthermore, aged rats show impairments in the water-maze paradigm, and a 1 mg/kg dose of DCS was found to lessen the age difference between aged and young rats in both place discrimination and repeated acquisition tests (104). In addition, DCS has been reported to reverse the memory retention deficit associated with senescence-accelerated mice (96).

Some researchers and clinicians have advocated the investigation of DCS for the symptomatic treatment of Alzheimer's disease (AD), a neurodegenerative disease characterized clinically by learning and memory deficits (1,105,106). Post-mortem AD brains exhibit a selective impairment in the coupling of the glycine binding site with the glutamate binding site of the NMDA receptor complex, as measured by the reduced amount of glycine-stimulated $[^3]H$MK-801 binding in AD brains as compared with control brains (107). This finding may result from a decrease in the number of NMDA receptor complex-associated glycine binding sites, or in the sensitivity of these glycine binding sites. Therefore, the potential exists for clinical improvement in AD patients through the administration of glycine agonists. In a small pilot study of six patients with probable AD, five patients exhibited improvements with a dose of either 5 mg/kg or 15 mg/kg of DCS administered over a seven-day period (1). A much larger study, which employed 108 patients with probable AD, found that 15 mg of DCS administered twice daily significantly enhanced implicit learning and retention over a three-day period (108). In contrast, a similar study which included 12 patients with probable AD, found no significant or consistent improvement in cognitive function (109). However, it is clear that these studies are too preliminary to reach a judgment on the clinical efficacy of DCS in the treatment of AD.

Because a functional interaction between the glutamatergic and dopaminergic pathways exists, the use of glycine agonists has been postulated as a treatment for schizophrenia, a disorder in which the underlying pathology has been attributed to an excessive stimulation of dopaminergic pathways (110). The increase in dopaminergic activity in schizophrenia may be related to a decrease in glutamatergic transmission (1), and this hypothesis has been corroborated by the low levels of glutamate found in the CSF of patients with schizophrenia (111). In addition, DCS was found to inhibit the hypermotility in rats induced by the administration of methamphetamine, which increases dopaminergic transmission. Similarly, DCS inhibited the behavioral responses elicited by selective stimulation of the D1 or D2 dopamine receptor subtypes (112). DCS was also reported in rats to enhance the neuroleptic activity of D1 and D2 receptor blockers (113), and
to decrease both the number and function of these dopamine receptors, leading to a decrease in dopaminergic transmission (114). Therefore, DCS might be able to antagonize the effect of elevated dopamine levels seen in schizophrenic patients through the stimulation of the NMDA receptor complex.

However, DCS elicited little response when it was utilized in a mouse hyperactivity model of psychosis (115). Furthermore, in a clinical trial of seven patients with chronic schizophrenia who received 250 mg of DCS as an adjuvant to conventional neuroleptics, only one patient exhibited a slight improvement (77). Interestingly, this patient was the only patient with the catatonic type of schizophrenia enrolled in the study. In contrast, a daily dose of 50 mg of DCS significantly reduced the negative symptoms and significantly improved the reaction time of nine patients with chronic schizophrenia when combined with conventional neuroleptics (116). Therefore, DCS may still prove to be beneficial in the treatment of certain forms or of certain symptoms of schizophrenia, and further investigations are warranted. Similarly, glycine partial agonists and glycine antagonists may also be effective in the treatment of other disorders such as Parkinson's disease, in which the antagonism of glutamatergic transmission may lead to a reversal of the decreased activity of the dopaminergic pathways (70).

One investigator has envisioned the administration of low doses of glycine agonists for use in conditions of memory impairment without associated neuro- degeneration, and the use of high doses of these compounds in cognitive impairments with associated neurodegeneration, or in the aging brain (106). It has been suggested that the efficacy of DCS may be attributed to the relief of excessive glutamate antagonism from kynurenic acid, an endogenous glutamate receptor antagonist whose levels have been shown to increase in conditions associated with cognitive deficits (117). Furthermore, some pathological conditions may be related to the dysfunction of the glycine transporter, for which glycine partial agonists could be useful in antagonizing the saturation of the NMDA receptor-associated glycine binding site, without the complete antagonism seen with glycine antagonists.

However, the clinical efficacy of compounds such as DCS is questionable, as chronic exposure to these drugs has frequently led to desensitization. A dose of 3 mg/kg of DCS, which had previously been reported to facilitate the retention of a thirst-motivated linear-maze task with acute post-training injections, failed to exhibit an increase in retention when administered to mice for 15 days, with a subsequent acute post-training injection (66). The desensitization seen in this experiment was postulated by the investigators to be produced by a nitric oxide-induced downregulation of the NMDA receptor complex. This scenario is unlikely, however, because chronic exposure to DCS had no effect on the protection to glutamate neurotoxicity exhibited by NMDA antagonists, indicating that the receptor was still present after chronic DCS administration (85).

This author suggests that the NMDA receptor-associated glycine site may undergo selective desensitization, independent of the glutamate binding sites. Therefore, the glycine binding site may ‘uncouple’ from the rest of the NMDA receptor complex. This hypothesis is corroborated by the finding that while the NMDA antagonists retained efficacy in the culture system above, compounds that act at the glycine binding site exhibited reduced neuroprotection after chronic exposure to DCS (85). This uncoupling of the glycine binding site from the NMDA receptor-associated glutamate binding site superficially resembles the state of the NMDA receptor complex in AD, in which the efficacy of glycine at this binding site is also reduced (107). Therefore, it is conceivable that some of the pathology in AD may be related to excessive stimulation of the NMDA receptor-associated glycine binding site, which could result from dysfunctional ECF glycine regulation. However, this hypothesis needs to be examined in further detail.

CONCLUSION

The nootropic effect of DCS in rats and mice for certain tasks appears to be well-established, although each task analyzed has revealed a different optimal dose. However, the nootropic properties of DCS have not been consistently seen in human and non-human primate models. The lack of response to DCS in these studies
may reflect the shifting dose-response curve that is found in the rat and mouse studies. Therefore, subsequent studies in humans and non-human primates will need to examine multiple doses of DCS before a conclusion can be drawn about the nootropic efficacy of this compound. The optimal dose of DCS for particular tasks has been found to be as low as 1 mg/kg in rats (100), and the CNS concentrations of DCS in rats at this dose may be as low as 0.2 mg/kg. Similarly, the studies in humans reporting that DCS enhanced learning and memory utilized a CNS concentration of DCS of approximately 0.2 mg/kg (estimated for a 70 kg individual with free access of the drug across the blood-brain barrier) (1,102). In contrast, studies suggesting that DCS has no nootropic activity in humans and non-human primates utilized a dose of DCS that was at least twice this concentration (101,109).

Although further investigations into the actions of DCS are required, especially those that utilize humans and non-human primates, this compound holds promise for the symptomatic treatment of disorders such as Alzheimer's disease, schizophrenia, Parkinson's disease, and the cognitive dysfunction associated with aging. Furthermore, the issue of DCS-induced desensitization of the NMDA receptor-associated glycine binding site needs to be addressed before DCS can be considered as a potential therapeutic for these chronic disorders.

REFERENCES


28. Hood WF, Compton RP, Monahan JB. N-methyl-D-aspartate recognition site ligands modulate activity at


40. Ascher P. Measuring and controlling the extracellular glycine concentration at the NMDA receptor level. Advances in Experimental Medicine and Biology 268: 13-16; 1990.


74. Watson GB, Bolanowski MA, Baganoff MP, et al. D-cycloserine acts as a partial agonist at the glycine


---

**BIOGRAPHY**

**Jason W. Allen** received a B.S. in Cellular and Molecular Biology from Tulane University (New Orleans, Louisiana, USA) in 1993. He is presently a third-year M.D./Ph.D. student at Georgetown University (Washington, D.C., USA) in the Interdisciplinary Program in Neuroscience. His research on D-cycloserine was conducted during his first year of graduate school at Georgetown University.

Copyright © 1996 by MJM